Literature DB >> 28521490

Transcript levels of ten-eleven translocation type 1-3 in cervical cancer and non-cancerous cervical tissues.

Dorota Ewa Bronowicka-Kłys1, Andrzej Roszak2,3, Piotr Pawlik4, Stefan Sajdak4, Anna Sowińska5, Paweł Piotr Jagodziński1.   

Abstract

Decreased expression of ten-eleven translocation (TET1, TET2 and TET3) proteins has been reported in various types of cancer. However, the expression levels of TET proteins in cervical cancer (CC) remain to be elucidated. The present study determined the levels of TET1, TET2 and TET3 transcripts in cancerous (n=80) and non-cancerous cervical tissues (n=41). The results revealed a significant reduction in TET1 transcripts (P=0.0000001) in cervical tissue samples from patients with primary CC compared with samples from control patients. Significantly decreased TET1 transcript levels, as compared to non-cancerous cervical tissues, were also observed in tissue samples with the following characteristics: Stage I (P=0.016), II (P<0.0001), III (P=0.00007) and grade of differentiation G1 (P=0.026), G2 (P=0.00006), G3 (P=0.0007) and Gx (P=0.0004) and squamous histological type (P<0.00001). TET1 transcript levels were significantly lower in patients aged 45-60 years (P=0.0002) and patients age >60 years (P=0.003), as compared with non-cancerous cervical tissues. TET2 transcript levels were lower in cervical cancer tissues classified as stage II (P=0.043) and TET3 transcript levels were lower in stage III samples (P=0.010), tissue samples with a grade of differentiation of G3 (P=0.025) and tissue with squamous type histology (P=0.047), all compared with non-cancerous cervical tissues. The present study demonstrated a significantly reduced level of TET1 transcripts in cancerous cervical tissues, as compared with non-cancerous tissues. Furthermore, decreased TET1-3 transcript levels were identified when patients with CC were stratified by clinicopathological variables, as compared with non-cancerous cervical tissues.

Entities:  

Keywords:  cervical cancer; ten-eleven translocation 1-3

Year:  2017        PMID: 28521490      PMCID: PMC5431291          DOI: 10.3892/ol.2017.5930

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

Review 1.  [Role of 5-hydroxymethylcytosine and TET proteins in epigenetic regulation of gene expression].

Authors:  Sylwester Głowacki; Janusz Błasiak
Journal:  Postepy Biochem       Date:  2013

2.  Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA.

Authors:  Yu-Fei He; Bin-Zhong Li; Zheng Li; Peng Liu; Yang Wang; Qingyu Tang; Jianping Ding; Yingying Jia; Zhangcheng Chen; Lin Li; Yan Sun; Xiuxue Li; Qing Dai; Chun-Xiao Song; Kangling Zhang; Chuan He; Guo-Liang Xu
Journal:  Science       Date:  2011-08-04       Impact factor: 47.728

Review 3.  Epigenetics and cervical cancer: from pathogenesis to therapy.

Authors:  Jinchuan Fang; Hai Zhang; Sufang Jin
Journal:  Tumour Biol       Date:  2014-02-20

Review 4.  [Oxidation and deamination of nucleobases as an epigenetic tool].

Authors:  Jolanta Guz; Marek Jurgowiak; Ryszard Oliński
Journal:  Postepy Hig Med Dosw (Online)       Date:  2012-05-24       Impact factor: 0.270

5.  [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics].

Authors:  W Böcker
Journal:  Verh Dtsch Ges Pathol       Date:  2002

6.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

7.  Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth.

Authors:  Xiaohong Wang; Shuang Tang; Shu-Yun Le; Robert Lu; Janet S Rader; Craig Meyers; Zhi-Ming Zheng
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

8.  Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.

Authors:  Min Fan; Xiaozhou He; Xianlin Xu
Journal:  Mol Med Rep       Date:  2015-07-08       Impact factor: 2.952

9.  Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1.

Authors:  Chungang Liu; Limei Liu; Xuejiao Chen; Junjie Shen; Juanjuan Shan; Yanmin Xu; Zhi Yang; Lin Wu; Feng Xia; Ping Bie; Youhong Cui; Xiu-wu Bian; Cheng Qian
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

10.  Acute loss of TET function results in aggressive myeloid cancer in mice.

Authors:  Jungeun An; Edahí González-Avalos; Ashu Chawla; Mira Jeong; Isaac F López-Moyado; Wei Li; Margaret A Goodell; Lukas Chavez; Myunggon Ko; Anjana Rao
Journal:  Nat Commun       Date:  2015-11-26       Impact factor: 14.919

View more
  6 in total

Review 1.  Ten-eleven translocase: key regulator of the methylation landscape in cancer.

Authors:  Jyoti Shekhawat; Kavya Gauba; Shruti Gupta; Bikram Choudhury; Purvi Purohit; Praveen Sharma; Mithu Banerjee
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-28       Impact factor: 4.553

2.  TET1 Isoforms Have Distinct Expression Pattern, Localization and Regulation in Breast Cancer.

Authors:  Mahmoud Alzahayqa; Abrar Jamous; Areej A H Khatib; Zaidoun Salah
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

Review 3.  Epigenetic Regulation of p21cip1/waf1 in Human Cancer.

Authors:  Matthias Ocker; Samar Al Bitar; Ana Carolina Monteiro; Hala Gali-Muhtasib; Regine Schneider-Stock
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

Review 4.  Epigenetic Dysregulation at the Crossroad of Women's Cancer.

Authors:  Rakesh Kumar; Aswathy Mary Paul; Pranela Rameshwar; M Radhakrishna Pillai
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

5.  Differential Expression of Steroid Hormone Receptors and Ten Eleven Translocation Proteins in Endometrial Cancer Cells.

Authors:  Vishakha Mahajan; Palak Gujral; Lekha Jain; Anna P Ponnampalam
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244

6.  Expression and prognosis analysis of TET family in acute myeloid leukemia.

Authors:  Tingjuan Zhang; Yangli Zhao; Yangjing Zhao; Jingdong Zhou
Journal:  Aging (Albany NY)       Date:  2020-03-25       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.